Locum Medical Advisory vs Retained Consulting in Biopharma

It appears as delayed decisions, fragmented clinical ownership, slow protocol development, weak regulatory preparation, and a pipeline that advances without a coherent medical strategy.

A permanent senior medical search typically takes around 90 days from start to completion. For an organization preparing a clinical milestone, responding to regulatory feedback, evaluating a clinical asset, or raising capital, that is not an administrative interval. It is an operational exposure.

This is where the distinction between locum medical advisory and retained consulting in biopharma becomes decisive. Both models can provide experienced medical expertise. They do not provide the same level of integration, accountability, or strategic continuity. Selecting the wrong structure creates a second bottleneck while appearing to solve the first.

Your organization needs to determine whether it requires temporary medical capacity, embedded executive leadership, or a deliberately staged combination of both.

The 90-day gap: why timing changes the decision

A permanent Chief Medical Officer or senior medical executive is not interchangeable with an external advisor brought in for a defined period. The permanent search may be the correct long-term strategy, but the search itself does not lead a clinical program, review an asset, prepare the board, or stabilize a medical function.

The 90-day average search timeline creates a predictable gap between recognizing the leadership need and appointing the permanent executive. That gap becomes more consequential when the company is operating at a transition point:

• A clinical trial is moving into a more complex stage of execution.
• A protocol requires redesign or stronger medical ownership.
• A regulatory engagement demands senior clinical judgment.
• A due diligence process requires independent review of a clinical asset.
• The board needs a credible medical narrative for financing or strategic decisions.
• A growing biotech has outpaced its internal medical operating model.
• A departing medical leader has left decisions, relationships, or documentation insufficiently transferred.

In these conditions, waiting for the permanent hire is not neutral. It transfers responsibility to a less prepared team, increases pressure on founders or chief executive officers, and can force clinical and commercial decisions into the same unstructured queue.

A locum medical advisor can provide rapid cover. A fractional medical leader can create continuity while the executive search proceeds. A retained consulting arrangement can provide deeper strategic support without requiring a full-time appointment. The central question is not which model is more prestigious. It is which model removes the actual bottleneck.

A 90-day executive search is a hiring timeline. It is not a clinical operating plan.

The first diagnostic step is to define the exposure created by the vacancy. If the immediate requirement is decision coverage, a locum medical director engagement may be appropriate. If the organization needs a medical function designed, governed, and connected to the executive team, a fractional or retained model is more likely to deliver the required result.

Defining the scope: locum advisory versus retained executive integration

The terms used in pharmaceutical medicine consulting are often applied too loosely. That creates avoidable confusion during procurement and onboarding.

A short-term project consultant is usually engaged around defined deliverables. The consultant may assess a protocol, review a clinical development plan, support a regulatory preparation process, or provide an independent medical opinion. Once the agreed work is completed, the engagement can close.

A locum medical advisor is more closely associated with temporary capacity. The organization needs an experienced physician or medical leader to cover a gap, support a defined period, or maintain continuity while a permanent solution is established. The role can be highly operational, but its boundaries must be explicit. Temporary presence does not automatically mean executive integration.

A fractional Chief Medical Officer or retained medical consultant operates differently. This professional is integrated into the leadership system and contributes across an ongoing set of decisions. The work may include clinical roadmap design, executive leadership participation, board interactions, fundraising support, regulatory strategy, and oversight of external clinical partners.

The distinction can be framed through the operating question each model answers:

• Locum advisory: Who can provide experienced medical coverage now?
• Project consulting: Which defined medical problem must be solved?
• Fractional medical leadership: Who will own the medical agenda while the organization scales?
• Retained consulting: Which senior expertise must remain available across evolving strategic decisions?

The models can overlap in practice, but they should not be presented as identical. A locum advisor may be highly experienced yet remain limited in duration, authority, and organizational integration. A retained fractional CMO may work part-time but carry broader responsibility for clinical direction and executive alignment.

The procurement brief must therefore go beyond a title. Your organization should specify the decisions the external medical leader is expected to influence, the forums they will attend, the outputs they will own, and the authority they will have to escalate clinical risk.

Without that definition, the company may appoint a senior expert and still leave the underlying workflow unchanged.

The value of 20+ years of leadership experience

The seniority of the external medical leader matters because biopharma medical work is rarely a sequence of isolated technical tasks. Clinical trial design, execution, regulatory engagement, and pipeline strategy affect one another. A decision that appears efficient in one workstream can create cost, evidence, or credibility problems in another.

Fractional CMOs and interim medical leaders typically bring at least 20 years of senior leadership experience across these interconnected areas. The value is not simply a longer résumé. It is the ability to recognize second-order consequences before they become operational failures.

A senior pharmaceutical medicine specialist can help you distinguish between:

• A protocol issue that requires immediate redesign and one that can be managed through implementation controls.
• A regulatory question that needs formal medical leadership and one that can be resolved through clearer documentation.
• A promising clinical asset with a genuine development path and one whose apparent opportunity depends on unsupported assumptions.
• A staffing problem and a governance problem.
• A temporary workload spike and a structural capacity deficit.
• A board concern that reflects inadequate evidence and one that reflects inadequate communication of the evidence.

That diagnostic capacity is especially relevant in biotech, where the medical organization may still be forming. The company may have strong scientific founders, capable clinical operations partners, and external vendors, but no senior physician accountable for the clinical narrative connecting them.

A locum advisor can stabilize the immediate workstream. A fractional CMO can establish the operating framework around it.

This difference becomes clear in clinical asset due diligence. An external medical reviewer may assess the scientific and clinical merits of an asset against a defined question. A retained medical leader may take that assessment further by connecting it to the portfolio, development sequence, resource plan, regulatory strategy, and board decision.

Neither model is automatically superior. The failure occurs when the organization commissions a narrow review while expecting broad strategic ownership.

What senior medical leadership should bring to the table

Your selection process should test for applied leadership, not only therapeutic-area familiarity. The strongest candidate will be able to move between detail and decision without losing control of either.

Look for evidence of the ability to:

• Translate clinical data into a development recommendation that the executive team can act on.
• Build a medical roadmap that aligns with trial execution, regulatory interactions, and pipeline priorities.
• Challenge assumptions without creating unnecessary friction between medical, scientific, operational, and commercial teams.
• Establish escalation routes for emerging clinical or safety concerns.
• Represent the medical function credibly in board-level discussions.
• Support fundraising with a disciplined clinical narrative rather than promotional language.
• Identify where external vendors are delivering efficiently and where the organization has outsourced judgment rather than execution.
• Create documentation and decision records that survive leadership transition.

This is where the phrase operationalize becomes more than management vocabulary. The external leader must convert medical strategy into decision rights, meeting structures, review points, and accountable actions. A strategy that remains in presentation materials is not a functioning medical system.

Engagement capacity: from less than 0.5 FTE to full-time leadership

Flexible capacity is one of the principal advantages of interim and fractional medical advisory structures. The engagement can be configured at less than 0.5 FTE, 0.5 FTE, or 1.0 FTE, depending on the organization’s needs.

The number alone does not define the model. A 0.5 FTE engagement can be highly effective if the mandate is narrow, the decision calendar is predictable, and the organization has capable operational support. It will fail if the company expects full-time availability, continuous stakeholder management, and ownership of multiple unstable workstreams.

Similarly, a 1.0 FTE interim appointment is not automatically equivalent to a permanent Chief Medical Officer. The duration, authority, governance expectations, and transition plan remain different. Full-time capacity addresses availability. It does not by itself create long-term organizational ownership.

Use capacity as a design variable rather than as a proxy for importance.

Less than 0.5 FTE

This structure can support a focused advisory mandate, including:

• Periodic review of clinical strategy.
• Independent medical assessment of a specific asset.
• Preparation for defined regulatory or board interactions.
• Oversight of a limited number of clinical decisions.
• Senior input during a targeted fundraising or partnership process.

The organization must maintain a disciplined agenda. Every meeting should connect to a decision, risk, or milestone. If the company expects the advisor to absorb unplanned operational work, the engagement will quickly exceed its intended capacity.

0.5 FTE

Half-time engagement is often suitable when a biotech needs sustained medical leadership but does not yet justify, or cannot yet support, a full-time executive appointment.

At this level, the medical leader may participate in executive meetings, guide the clinical roadmap, oversee external clinical partners, support board preparation, and maintain continuity across a developing program. The company must still assign internal owners for operational execution.

The central risk is hidden dependency. A fractional CMO should not become an informal full-time executive without the authority, access, and resourcing associated with that expectation.

1.0 FTE

Full-time interim medical leadership is appropriate when the organization has a concentrated period of high activity or a significant vacancy affecting multiple functions. The role may include day-to-day leadership, clinical development decisions, regulatory engagement, cross-functional coordination, and transition support for the incoming permanent executive.

This model requires the clearest governance design. A full-time interim leader will encounter decisions that sit at the boundary between medical, clinical operations, regulatory, safety, and corporate strategy. If those boundaries are not established, the appointment becomes a high-cost routing mechanism rather than a leadership solution.

The following framework helps match the engagement to the operating problem:

1. Map the decision load. Count the material clinical, regulatory, board, and pipeline decisions expected during the engagement. Do not count meetings; count decisions.

2. Identify the failure point. Determine whether the constraint is missing expertise, missing authority, insufficient capacity, or weak process design.

3. Set the required integration level. Specify whether the advisor attends executive meetings, interacts with the board, directs vendors, approves medical positions, or provides independent review only.

4. Choose the capacity band. Select less than 0.5 FTE, 0.5 FTE, or 1.0 FTE based on the workload and response expectations.

5. Define the transition. Establish what happens when the permanent hire joins, the trial milestone passes, or the asset decision is completed.

This sequence prevents a common procurement error: selecting an engagement format before diagnosing the organization’s actual need.

Fractional does not mean peripheral. It means the organization has deliberately allocated senior capacity without appointing a conventional full-time executive.

Governance and accountability: the integration test

The most important difference between locum medical advisory and retained consulting is often governance rather than expertise.

A senior external physician may have the knowledge required to make a strong recommendation. Your organization still needs to determine how that recommendation enters the decision system. Who receives it? Who acts on it? Who records the rationale? Who escalates a disagreement? Who remains accountable when the external engagement ends?

These questions are not contractual decoration. They determine whether the engagement produces durable clinical control.

A locum medical advisor can be given a defined remit with clear escalation routes. For example, the advisor may review a trial issue, advise the executive team, and support continuity during a leadership vacancy. The organization retains responsibility for determining how those recommendations are adopted and documented.

A retained fractional leader is usually expected to operate closer to the center of the organization. That can include ongoing oversight of the medical roadmap, participation in executive decisions, board interactions, and fundraising support. The wider the mandate, the more precisely the organization must define governance and accountability.

Decision rights must be explicit

Your engagement framework should answer at least five questions:

• Which decisions can the external medical leader make directly?
• Which decisions require executive, board, or sponsor approval?
• Which matters must be escalated immediately?
• Which functions remain under clinical operations, regulatory, safety, or commercial leadership?
• What information must be available for the medical leader to discharge the role properly?

Avoid vague language such as overall medical support or strategic input. These phrases create expectations without creating authority. Replace them with operational terms: review, recommend, approve, escalate, chair, present, document, or transition.

The same discipline applies to interactions with contract research organizations and other external partners. If the medical leader is expected to challenge trial execution, the engagement must provide access to the relevant data, meeting forums, and accountable operational owners. Otherwise, the leader is being asked to identify risk without the means to resolve it.

P&L and organizational responsibility are not implied

A retained consultant and an interim executive can both influence high-value decisions, but their organizational roles may differ materially. Do not assume that an advisory title carries responsibility for the company’s profit and loss, corporate governance, or formal executive obligations.

Likewise, do not assume that a locum medical advisor and a retained fractional CMO perform identical work simply because both are experienced physicians. Their integration, accountability, duration, and relationship with the board may be different.

If the organization needs formal executive ownership, appoint that responsibility deliberately. If it needs independent medical judgment, preserve the independence of the review. If it needs both, separate the functions or document how potential conflicts will be handled.

This is particularly important during clinical asset due diligence. The reviewer may need to assess the evidence independently, while the executive team may want a recommendation connected to portfolio strategy. Those are related outputs, but they are not the same output.

Selection: test for operating fit, not availability

A senior medical consultant can be impressive in conversation and ineffective inside your workflow. The selection process must therefore focus on operating fit.

Assess the candidate against the specific failure pattern you are trying to correct:

If the problem is a leadership vacancy

Prioritize interim leadership experience, executive communication, decision velocity, and the ability to create continuity while the permanent search continues. The candidate should be able to enter an established organization without creating unnecessary disruption.

If the problem is an immature medical function

Prioritize framework design, clinical roadmap development, governance, vendor oversight, and the ability to build repeatable processes. The engagement must leave the organization more scalable than it was at the start.

If the problem is an asset decision

Prioritize independent medical review, clinical development judgment, evidence assessment, and the ability to communicate uncertainty without inflating or dismissing the opportunity.

If the problem is fundraising or board confidence

Prioritize the ability to construct a credible medical narrative, connect clinical evidence to development strategy, and explain the decision logic in language appropriate for non-clinical stakeholders.

If the problem is trial execution

Prioritize experience in protocol design, operational oversight, risk escalation, and cross-functional accountability. The consultant must be able to identify whether the issue is a clinical design flaw, a delivery failure, or a breakdown in oversight.

A practical assessment can use a short scenario rather than a generic interview. Give the candidate a clinical or organizational problem relevant to the engagement and ask them to outline:

• The first information they would request.
• The immediate risk they would isolate.
• The decisions that cannot wait.
• The stakeholders they would involve.
• The recommendation they would take to the executive team.
• The controls they would put in place for the following weeks.

This reveals how the candidate thinks under pressure. It also shows whether they default to analysis without action, or whether they can convert expertise into an operating framework.

Building a scalable model rather than renting expertise

The strongest pharmaceutical medicine consulting engagement does not merely fill a vacancy. It improves the organization’s ability to make and execute medical decisions after the engagement changes.

That requires a deliberate knowledge-transfer plan. The external leader should not remain the only person who understands the rationale behind a clinical roadmap, a regulatory position, or a pipeline recommendation. Key decisions need documented logic, assigned ownership, and a clear record of unresolved issues.

Your organization should expect the engagement to produce practical infrastructure, such as:

• A current medical and clinical development roadmap.
• Defined decision rights across medical, clinical operations, regulatory, safety, and executive functions.
• A prioritized register of clinical and operational risks.
• A documented approach to board and investor communication.
• A transition record for the incoming permanent leader.
• A clear list of decisions pending additional data or external input.
• A repeatable cadence for clinical review and executive escalation.

This is where scalability is tested. If every decision still depends on one external individual’s memory, the company has purchased access but not built capability.

The retained model is particularly valuable when the organization is moving through several linked milestones. A fractional leader can maintain continuity across the pipeline, board, regulatory, and fundraising agendas. A locum engagement may be more efficient when the need is concentrated and the endpoint is clear.

The right structure can also evolve. A company may begin with a locum medical advisor to stabilize an immediate gap, move to a fractional CMO arrangement during a clinical development phase, and then transition to a permanent medical executive. That progression should be designed at the outset rather than allowed to emerge through repeated extensions.

The strategic mandate for your organization

The choice between locum medical advisory and retained consulting in biopharma should be made through a structured operating decision, not through title preference or short-term availability.

Use this mandate:

1. Define the exposure created by the gap. State which decisions, milestones, or governance functions are at risk during the permanent search or organizational transition.

2. Separate temporary coverage from strategic ownership. Decide whether you need a locum advisor, a project consultant, a fractional medical leader, or a combination of these models.

3. Specify the scope in decision language. Define what the external leader will review, recommend, direct, escalate, present, and transition.

4. Match capacity to workload. Select less than 0.5 FTE, 0.5 FTE, or 1.0 FTE based on decision volume and integration requirements—not on an arbitrary preference for part-time or full-time support.

5. Test seniority in context. Seek the judgment associated with 20+ years of clinical leadership, but assess how that experience will be applied to your program, governance structure, and pipeline.

6. Build accountability into the engagement. Document decision rights, reporting lines, board access, vendor interaction, and the boundaries between advisory and executive responsibility.

7. Require capability transfer. The engagement should leave behind a stronger roadmap, clearer governance, and a more scalable medical operating system.

8. Set the transition before the start. Define the endpoint, the handover requirements, and the circumstances under which the engagement will expand, reduce, or close.

A locum medical director engagement is not a substitute for every form of medical leadership. Retained consulting is not automatically the better answer because it sounds more strategic. Each model has a distinct operating purpose.

Your task is to remove the bottleneck without creating a new one. Choose the structure that gives the organization the required medical judgment, at the required level of integration, for the decisions that cannot be deferred.